Skip to content

Study · Non-randomized trial · n = 30 · 1984

3 results

Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH.

Gudmundsson JA, Nillius SJ, Bergquist C

Contraception1 Aug 1984Cited by 13 (Europe PMC)

PMID6238805 (opens in a new tab)DOI10.1016/0010-7824(84)90094-5 (opens in a new tab)PepBankPUB-06238805
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In 30 healthy women, nafarelin inhibited ovulation throughout 89 cumulative months of therapy during the 3-month study.

    In plain wordsIn healthy women, nafarelin inhibited ovulation throughout 89 cumulative treatment months in a 3-month study.

    Peptide
    Nafarelin
    Outcome
    DecreaseOvulation inhibition
    Study

    n = 30

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    125 or 250 micrograms daily · intranasal · 3 monthsAs given in this study (human).

    Measurements

    Cumulative therapy
    89 months
    reported result

    Source sentences

    Summary
    The treatment inhibited ovulation in all women during the 89 months of therapy.
    2 context sentences
    Summary · context
    Thirty healthy female volunteers used a new superactive stimulatory analog of the hypothalamic gonadotropin-releasing hormone (GnRH) for inhibition of ovulation and contraception during 3 months.
    Summary · context
    The potent GnRH agonist nafarelin (D-Nal(2)6-GnRH) was administered intranasally in a daily dose of 125 micrograms to 15 women and 250 micrograms to 15 women.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy women, nafarelin decreased mean estradiol within the normal early to mid-follicular range during treatment.

    In plain wordsIn healthy women, nafarelin reduced mean estradiol within the normal early to mid-follicular range.

    Peptide
    Nafarelin
    Outcome
    DecreaseMean estradiol concentration
    Study

    n = 30

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    125 or 250 micrograms daily · intranasal · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The mean estradiol concentration decreased during the 3-month treatment within the normal range for the early to mid-follicular phase of the menstrual cycle.
    2 context sentences
    Summary · context
    Thirty healthy female volunteers used a new superactive stimulatory analog of the hypothalamic gonadotropin-releasing hormone (GnRH) for inhibition of ovulation and contraception during 3 months.
    Summary · context
    The potent GnRH agonist nafarelin (D-Nal(2)6-GnRH) was administered intranasally in a daily dose of 125 micrograms to 15 women and 250 micrograms to 15 women.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women receiving nafarelin, no pregnancies occurred during 59 treatment months without additional contraceptives.

    In plain wordsIn women receiving nafarelin, no pregnancies occurred during 59 treatment months without additional contraceptives.

    Peptide
    Nafarelin
    Outcome
    Not applicablePregnancies without additional contraception
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    125 or 250 micrograms daily · intranasal · 3 monthsAs given in this study (human).

    Measurements

    Treatment months without additional contraceptives
    59 months
    nafarelin 125 or 250 micrograms daily

    Source sentences

    Summary
    No pregnancies occurred during 59 treatment months in which no additional contraceptives were used.
    2 context sentences
    Summary · context
    Thirty healthy female volunteers used a new superactive stimulatory analog of the hypothalamic gonadotropin-releasing hormone (GnRH) for inhibition of ovulation and contraception during 3 months.
    Summary · context
    The potent GnRH agonist nafarelin (D-Nal(2)6-GnRH) was administered intranasally in a daily dose of 125 micrograms to 15 women and 250 micrograms to 15 women.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.